Clinical and economic implications of using daratumubab with lenalidomide in the 1st and 2nd lines of therapy for multiple myeloma patients
Objective: to assess clinical and economic implications of adding daratumumab (Dara) to the "lenalidomide + dexamethasone" (Rd) treatment program in early lines of therapy for patients with multiple myeloma (MM) ineligible for high-dose chemotherapy (HDCT) with subsequent autologous hemato...
Saved in:
Main Authors: | , , |
---|---|
Format: | Book |
Published: |
IRBIS LLC,
2024-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!